{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:18:40Z","timestamp":1761743920295},"reference-count":54,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6,1]]},"abstract":"<jats:sec><jats:title>Context:<\/jats:title><jats:p>GH deficiency (GHD) may occur in adults with cured acromegaly (acroGHD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>Our objective was to examine the effectiveness and safety of GH replacement in acroGHD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design:<\/jats:title><jats:p>This study was a retrospective analysis of data from KIMS (Pfizer International Metabolic Database).<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting:<\/jats:title><jats:p>Data were extracted from a pharmaco-epidemiological survey of &amp;gt;16 000 GHD adults from 31 countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients:<\/jats:title><jats:p>The effectiveness population included 115 adults with acroGHD and 142 age-, gender-, and body mass index-matched GHD adults with nonfunctioning pituitary adenoma (NFPA) followed up to 5 years on GH. The safety population included 164 adults with acroGHD and 2469 with NFPA, all GH-replaced. Both acroGHD and NFPA were compared with several cohorts from the general population (including the World Health Organization Global Burden of Disease).<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcome Measures:<\/jats:title><jats:p>Outcome measures included quality of life (QoL-AGHDA), lipids, serious adverse events, and additional safety endpoints.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Median GH dose was 0.3 mg\/d in acroGHD and NFPA at 5 years. There were comparable improvements in QoL-AGHDA and total and low-density lipoprotein cholesterol in acroGHD and NFPA. High-density lipoprotein cholesterol increased only in acroGHD. Cardiovascular mortality was increased in acroGHD vs NFPA (standardized mortality ratio = 3.03, P = .02). All-cause mortality was similar in acroGHD (ratio between observed\/expected cases [95% confidence interval] = 1.32 [0.70\u20132.25]) and lower in NFPA [observed\/expected = 0.58 [0.48\u20130.70]) in comparison with the general population. There was no difference in incidence of all cancers, benign or malignant brain tumors, or diabetes mellitus between acroGHD and NFPA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>GH replacement has comparable effects on quality of life and lipids in acroGHD and NFPA. Further investigation is needed to examine whether the increased cardiovascular mortality may be attributed to the history of previous GH excess in acroGHD.<\/jats:p><\/jats:sec>","DOI":"10.1210\/jc.2014-1013","type":"journal-article","created":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T15:37:34Z","timestamp":1396453054000},"page":"2018-2029","source":"Crossref","is-referenced-by-count":29,"title":["Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis"],"prefix":"10.1210","volume":"99","author":[{"given":"Nicholas A.","family":"Tritos","sequence":"first","affiliation":[{"name":"Neuroendocrine Unit (N.A.T., K.K.M., A.K., B.M.K.B.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudmundur","family":"Johannsson","sequence":"first","affiliation":[{"name":"Department of Endocrinology (G.J.), Gothenburg, Sweden SE-41345;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rta","family":"Korbonits","sequence":"first","affiliation":[{"name":"Department of Endocrinology (M.K.), Barts and the London School of Medicine, Queen Mary University of London, London, United Kingdom EC1M 6BQ;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen K.","family":"Miller","sequence":"first","affiliation":[{"name":"Neuroendocrine Unit (N.A.T., K.K.M., A.K., B.M.K.B.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulla","family":"Feldt-Rasmussen","sequence":"first","affiliation":[{"name":"Department of Medical Endocrinology (U.F.-R.), Rigshospitalet, National University Hospital, Copenhagen University, Copenhagen, Denmark DK-2100;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin C. J.","family":"Yuen","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Clinical Nutrition (K.C.J.Y.), Oregon Health and Science University, Portland, Oregon 97239;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"King","sequence":"first","affiliation":[{"name":"Pfizer, Inc (D.K.), New York, New York 10017;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders F.","family":"Mattsson","sequence":"first","affiliation":[{"name":"Sahlgrenska University Hospital (A.F.M.), Gothenburg, Sweden SE-41345;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Jonsson","sequence":"first","affiliation":[{"name":"Pfizer Endocrine Care (P.J.J., M.K.-H.), Sollentuna, Sweden SE-19091"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Koltowska-Haggstrom","sequence":"first","affiliation":[{"name":"Pfizer Endocrine Care (P.J.J., M.K.-H.), Sollentuna, Sweden SE-19091"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Klibanski","sequence":"first","affiliation":[{"name":"Neuroendocrine Unit (N.A.T., K.K.M., A.K., B.M.K.B.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beverly M. K.","family":"Biller","sequence":"first","affiliation":[{"name":"Neuroendocrine Unit (N.A.T., K.K.M., A.K., B.M.K.B.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071613155321100_B1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MED.0b013e32833b6bc7","article-title":"The diagnosis and treatment of growth hormone deficiency in adults","volume":"17","author":"Clemmons","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2020071613155321100_B2","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1210\/jc.2011-0179","article-title":"Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Molitch","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1530\/EJE-09-0222","article-title":"Prevalence of GH deficiency in cured acromegalic patients: impact of different previous treatments","volume":"161","author":"Ronchi","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"2020071613155321100_B4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/EJE-08-0496","article-title":"Cardiac manifestations of GH deficiency after treatment for acromegaly: a comparison to patients with biochemical remission and controls","volume":"159","author":"van der Klaauw","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"2020071613155321100_B5","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1210\/jc.2008-2671","article-title":"Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly","volume":"94","author":"Wexler","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2265.2012.04361.x","article-title":"Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly","volume":"77","author":"Lin","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613155321100_B7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1210\/jc.2009-1611","article-title":"Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement","volume":"95","author":"Miller","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4158\/EP11134.OR","article-title":"Effect of growth hormone replacement therapy on the quality of life in women with growth hormone deficiency who have a history of acromegaly versus other disorders","volume":"18","author":"Valassi","year":"2012","journal-title":"Endocr Pract"},{"key":"2020071613155321100_B9","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1210\/jc.2012-2477","article-title":"GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency","volume":"97","author":"Giavoli","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B10","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1210\/jc.2007-2673","article-title":"Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly","volume":"93","author":"Norrman","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/eje.0.1460067","article-title":"Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease","volume":"146","author":"Feldt-Rasmussen","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"2020071613155321100_B12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11102-009-0186-y","article-title":"Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly","volume":"12","author":"van der Klaauw","year":"2009","journal-title":"Pituitary"},{"key":"2020071613155321100_B13","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1210\/jc.2010-2662","article-title":"Unreplaced sex steroid deficiency, corticotropin deficiency, and lower IGF-I are associated with lower bone mineral density in adults with growth hormone deficiency: a KIMS database analysis","volume":"96","author":"Tritos","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B14","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1530\/EJE-07-0631","article-title":"Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia","volume":"157","author":"Ho","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2020071613155321100_B15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/1740028032000131396","article-title":"Thirty years of bioethics: the Helsinki Declaration 1964\u20132003","volume":"1","author":"Riis","year":"2003","journal-title":"New Rev Bioeth"},{"key":"2020071613155321100_B16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1023\/A:1008987922774","article-title":"The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency","volume":"8","author":"McKenna","year":"1999","journal-title":"Qual Life Res"},{"key":"2020071613155321100_B17","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"key":"2020071613155321100_B18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2337\/dc11-0449","article-title":"Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study","volume":"35","author":"Luger","year":"2012","journal-title":"Diabetes Care"},{"key":"2020071613155321100_B19","first-page":"1","article-title":"Global burden of disease in 2002: data sources, methods and results","volume-title":"Global Programme on Evidence for Health Policy","author":"Mathers","year":"2003"},{"key":"2020071613155321100_B20","volume-title":"Cancer Incidence in Five Continents","author":"Curado","year":"2007"},{"key":"2020071613155321100_B21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.diabres.2008.07.022","article-title":"Incidence of type 1 and type 2 diabetes in adults and children in Kronoberg, Sweden","volume":"82","author":"Thunander","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"2020071613155321100_B22","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.2337\/diabetes.53.7.1782","article-title":"Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study","volume":"53","author":"Bonora","year":"2004","journal-title":"Diabetes"},{"key":"2020071613155321100_B23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.amepre.2005.12.009","article-title":"Changes in incidence of diabetes in U.S. adults, 1997\u20132003","volume":"30","author":"Geiss","year":"2006","journal-title":"Am J Prev Med"},{"key":"2020071613155321100_B24","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archinte.162.1.82","article-title":"Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study","volume":"162","author":"Meisinger","year":"2002","journal-title":"Arch Intern Med"},{"key":"2020071613155321100_B25","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1464-5491.2009.02863.x","article-title":"Incidence of type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4\/F4 cohort study","volume":"26","author":"Rathmann","year":"2009","journal-title":"Diabet Med"},{"key":"2020071613155321100_B26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/cen.12132","article-title":"Predictors of the effects of 4 years of growth hormone replacement on bone mineral density in patients with adult-onset growth hormone deficiency - a KIMS database analysis","volume":"79","author":"Tritos","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613155321100_B27","first-page":"53","article-title":"Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study","volume":"60","author":"Brabant","year":"2003","journal-title":"Horm Res"},{"key":"2020071613155321100_B28","first-page":"69","article-title":"The design and analysis of cohort studies","volume-title":"Statistical Methods in Cancer Research","author":"Breslow","year":"1987"},{"key":"2020071613155321100_B29","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1210\/jcem.85.7.6699","article-title":"Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly","volume":"85","author":"Biermasz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1365-2265.2001.01189.x","article-title":"The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients","volume":"54","author":"Murray","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613155321100_B31","first-page":"326","article-title":"Severe growth hormone deficiency is rare in surgically-cured acromegalics","volume":"16","author":"Fujio","year":"2013","journal-title":"Pituitary"},{"key":"2020071613155321100_B32","first-page":"46","article-title":"Quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA): comparison of normative reference data for the general population of England and Wales with results for adult hypopituitary patients with growth hormone deficiency","volume":"64","author":"Ko\u0142towska-Haggstrom","year":"2005","journal-title":"Horm Res"},{"key":"2020071613155321100_B33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1530\/eje.1.02176","article-title":"Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life?","volume":"155","author":"Koltowska-H\u00e4ggstr\u00f6m","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"2020071613155321100_B34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1651-2227.1989.tb11242.x","article-title":"Quality of life of adults with growth hormone deficiency: a controlled study","volume":"356","author":"Bj\u00f6rk","year":"1989","journal-title":"Acta Paediatr Scand Suppl"},{"key":"2020071613155321100_B35","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/jcem.80.12.8530603","article-title":"Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial","volume":"80","author":"Burman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B36","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1210\/jc.2005-0439","article-title":"Quality of life in childhood onset growth hormone-deficient patients in the transition phase from childhood to adulthood","volume":"90","author":"Attanasio","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B37","first-page":"3184","article-title":"Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency","volume":"83","author":"Baum","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B38","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2265.2007.02935.x","article-title":"Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy","volume":"67","author":"Monson","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613155321100_B39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1530\/EJE-08-0448","article-title":"GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables","volume":"159","author":"Abrams","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"2020071613155321100_B40","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1210\/jc.2003-030840","article-title":"Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomized, placebo-controlled trials","volume":"89","author":"Maison","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B41","first-page":"153","article-title":"The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults","volume":"80","author":"Weaver","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in patients with pituitary disease","volume":"31","author":"Sherlock","year":"2010","journal-title":"Endocr Rev"},{"key":"2020071613155321100_B43","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1530\/EJE-11-1028","article-title":"Overall and cause-specific mortality in GH-deficient adults on GH replacement","volume":"166","author":"Gaillard","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2020071613155321100_B44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2265.2007.02947.x","article-title":"Excess mortality in women with pituitary disease: a meta-analysis","volume":"67","author":"Nielsen","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613155321100_B45","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1210\/jc.2013-2415","article-title":"Update in mortality in GH-treated patients","volume":"98","author":"Erfurth","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B46","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/jc.2012-3072","article-title":"A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy","volume":"98","author":"Annamalai","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B47","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11102-010-0284-x","article-title":"Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism","volume":"14","author":"Espinosa-de-los-Monteros","year":"2011","journal-title":"Pituitary"},{"key":"2020071613155321100_B48","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1365-2265.2011.04019.x","article-title":"The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly","volume":"75","author":"Jayasena","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613155321100_B49","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrendo.2010.171","article-title":"Growth hormone, the insulin-like growth factor axis, insulin and cancer risk","volume":"7","author":"Clayton","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"2020071613155321100_B50","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1210\/jc.2011-0112","article-title":"Long-term safety of growth hormone replacement after CNS irradiation","volume":"96","author":"Mackenzie","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B51","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/neuonc\/nos208","article-title":"Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review","volume":"14","author":"Braganza","year":"2012","journal-title":"Neuro Oncol"},{"key":"2020071613155321100_B52","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1586\/ern.09.98","article-title":"Radiation-induced gliomas","volume":"9","author":"Prasad","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"2020071613155321100_B53","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1210\/jc.2011-0448","article-title":"Prevalence and incidence of diabetes mellitus in adult patients on growth hormone replacement for growth hormone deficiency: a surveillance database analysis","volume":"96","author":"Attanasio","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613155321100_B54","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1530\/EJE-12-0807","article-title":"Prevalence of diabetes mellitus in 6050 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis","volume":"168","author":"Abs","year":"2013","journal-title":"Eur J Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/99\/6\/2018\/9048128\/jcem2018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/99\/6\/2018\/9048128\/jcem2018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T15:56:34Z","timestamp":1716652594000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/99\/6\/2018\/2537610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,1]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2014-1013","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,1]]}}}